David heads the seed fund at LifeArc and holds non-executive roles at Frontier IP Group and Oxford BioDynamics. He also advises RYSE Asset Management and mentors at Bruntwood SciTech.
Melanie brings extensive executive and scientific leadership experience, having served as chief executive officer at LifeArc and Syntaxin, alongside roles at BTGplc and NightstaRx.
Clare brings life sciences and venture experience from roles at LifeArc Ventures, Closed Loop Medicine, and the BioIndustry Association. She currently serves as director, chair, and board observer across various biotechnology organisations.
General Catalyst led the financing alongside a syndicate of new and existing investors to support the developer of antibody-based therapeutics.
"KnotBodies represent a potential breakthrough biologic drug modality, delivering greater potency, selectivity, and durability. We believe they will provide transformational new therapeutic options for ion channel- and GPCR-driven diseases across a wide range of therapeutic areas with a remaining high unmet medical need. The calibre of our international investor syndicate validates our approach, and I would like to welcome our new investors to Maxion and thank our existing investors for their continued support."
The funding round was led by Eka Ventures and will support international studies and product development.
"Existing data suggests that current approaches fall short at accurately detecting and localizing the deadliest cancers that desperately need to benefit from a blood test. At OXcan, we are using state-of-art and unbiased high-throughput proteomics approaches to examine hundreds and thousands of proteins in blood samples from largest studies of their kind for the first time. Combined with proprietary and tailored machine learning approaches, the results are products that fully integrate with existing care pathways and can detect and localize the deadliest cancers with unprecedented sensitivity and specificity."
The financing round was led by the Dementia Discovery Fund with backing from LifeArc and the UK Future Fund.
"We are delighted that DDF and LifeArc share our mission, addressing the clear need for more effective tools to provide the critical clinical trial data and analysis needed to improve the successful delivery of new CNS therapies to patients. This funding will allow us to build on the ground-breaking advances we have made in remote, frequent monitoring of brain activity and cognitive function in the home, in partnership with leading developers of digital biomarkers. We believe our integrated next generation platform can improve the execution of clinical trials by yielding significant time and cost savings, adding meaningful value to the next generation of CNS therapies."
The funding round was led by UK Innovation & Science Seed Fund with participation from LifeArc and Parkwalk.
"The increasing incidence of debilitating ophthalmic diseases brings morbidity and economic cost, and we are pleased to announce our seed funding today to tackle these urgent issues. We thank our investors UKI2S, LifeArc and Parkwalk for their support, and look forward to working with them to build Ikarovec into a leading gene therapy company."
